| Gene symbol | NKX3-2 | Synonyms | BAPX1, NKX3.2, NKX3B, SMMD | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | NK3 homeobox 2 | ||||
| GTO ID | GTC2677 |
| Trial ID | NCT04875754 |
| Disease | Knee Osteoarthritis |
| Altered gene | NKX3-2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | ICM-203 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2a, Double-Blind, Placebo-Controlled Single Dose Escalation Study of Intra-Articular ICM 203 in Subjects With Kellgren-Lawrence Grade 2 or Grade 3 Osteoarthritis of the Knee |
| Year | 2021 |
| Country | Australia |
| Company sponsor | ICM Biotech Australia Pty Ltd. |
| Other ID(s) | ICM 20-1001 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: dose level 3 | |||||||||||
|
|||||||||||